Nicotinamide Riboside and Pterostilbene Composition for Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Parkinson's disease, Alzheimer's, and Huntington's are inadequate in effectively alleviating symptoms and slowing disease progression, as they primarily focus on symptom reduction rather than addressing the underlying metabolic and neuronal health issues.
Innovation Solution
Administration of nicotinamide riboside and pterostilbene compositions to increase NAD+ levels and activate sirtuin enzymes, which are believed to promote neuronal health and metabolic homeostasis, thereby treating and preventing neurodegenerative diseases by improving cellular and brain function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prior art treatments (Levodopa, sirtuin activators) are administered, then dopamine concentration or sirtuin activity is increased, but adequate beneficial results are not achieved for neurodegenerative disorders
Solution Approach 1:
The patent combines two previously separate treatment approaches into a single composition: nicotinamide riboside (an NAD+ precursor) and pterostilbene (a sirtuin activator). This merging allows the composition to simultaneously increase NAD+ levels and activate sirtuin enzymes, addressing multiple pathological mechanisms of neurodegenerative disorders concurrently, thereby achieving adequate beneficial results that neither treatment could achieve alone.
Solution Approach 2:
The invention creates a composite therapeutic agent by formulating nicotinamide riboside and pterostilbene together in specific ratios (e.g., 1:1, 2:1, or 1:2 molar ratios). This composite composition leverages the synergistic effects of both compounds, where nicotinamide riboside provides the necessary NAD+ substrate and pterostilbene activates sirtuin enzymes, creating a more effective treatment than individual components.
2Reliability
If NAD+ levels are increased through supplementation, then sirtuin activity is enhanced, but the underlying metabolic and neuronal health issues are not adequately addressed
Solution Approach 1:
The patent uses pterostilbene as an intermediary compound that bridges the gap between NAD+ supplementation and sirtuin activation. Pterostilbene acts as a direct activator of sirtuin enzymes, mediating the translation of increased NAD+ levels into enhanced sirtuin activity and downstream neuroprotective effects, thereby addressing both metabolic and neuronal health issues through a coordinated mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of nicotinamide riboside and pterostilbene compositions leads to increased NAD+ levels and sirtuin activity, potentially slowing disease progression and reducing symptoms of neurodegenerative disorders by enhancing neuronal health and metabolic function.
Implementation Method 1
levels can be increased by providing supplementation of NAD+ via NAD+ precursors
Implementation Method 2
SIRT1, is a nicotinamide adenine dinucleotide (NAD+) dependent deacetylase
Implementation Method 3
sirtuin enzymes are believed to act by transferring an acetyl group from their substrate protein to the ADP-ribose moiety of NAD+
Data Source
AI summary
Compositions containing a combination of nicotinamide riboside and pterostilbene for treating neurodegenerative disorders, and methods of treating neurodegenerative disorders using these compositions and their equivalents are described. The neurodegenerative disorders that can be treated using these compositions or methods can include Parkinson's disease, Huntington's disease, Alzheimer's disease, and the like. In an embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene can be prepared as oral formulations. In some embodiments, a dietary supplement comprises nicotinamide riboside and/or pterostilbene or equivalents.